PEDIATRICS Vol. 100 No. 5 November 1997, pp. 767-771

MMR2 Immunization at 4 to 5 Years and 10 to 12 Years of Age: A Comparison of Adverse Clinical Events After Immunization in the Vaccine Safety Datalink Project

Received Dec 17, 1996; accepted Apr 7, 1997.

Robert L. Davis^*, Edgar Marcuse MD, Steven Black^§, Henry Shinefield^§, Ben Givens^*, Joan Schwalbe^§, Paula Ray^§, Robert S. Thompson^*, Robert Chen, and the Vaccine Safety Datalink Team^*

From the ^* Group Health Cooperative, Seattle, Washington;  Children's Hospital Medical Center, Seattle, Washington; ^§ Kaiser Permanente Vaccine Study Center, Oakland, California; and  National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia.

Background.  The Advisory Committee on Immunization Practices recommends a second dose of measles, mumps, and rubella vaccine (MMR2) at age 4 to 5 years of age, whereas the American Academy of Pediatrics suggests MMR2 immunization at age 11 to 12 years of age. Because there is little information on whether the rate of adverse reactions to MMR2 immunization varies among these two age groups, we took advantage of differing immunization policies at two large HMOs to compare the frequency of clinical events after, and possibly related to, MMR2 immunization.

Methods.  Information was collected on clinical events plausibly associated to MMR immunization (seizures, pyrexia, malaise/fatigue, nervous/musculoskeletal symptoms, rash, edema, induration/ecchymoses, lymphadenopathy, thrombocytopenia, aseptic meningitis, and joint pain) in two cohorts. At three facilities at Northern California Kaiser (Oakland, CA), 8514 children received MMR2 immunization at age 4 to 6 years of age; at Group Health Cooperative (Seattle, WA) 18 036 children received MMR2 immunization at age 10 to 12 years of age. To account for age-related differences in health care use, within each HMO, clinical events in a 30-day period after immunization were compared with a 30-day period before vaccination.

Results.  Children 10 to 12 years of age were 50% more likely to have a clinical event after MMR2 immunization than in the period before immunization (odds ratio, 1.45; 95% confidence interval: 1.00,2.10). Children 4 to 6 years of age were less likely to have a visit for an event after immunization compared with the period before immunization (odds ratio, 0.64; 95% confidence interval: 0.40,1.01).

Conclusions.  These results suggest that the risk for clinical events after MMR2 immunizations is greater in the 10- to 12-year age group.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. W. LeBaron, D. Bi, B. J. Sullivan, C. Beck, and P. Gargiullo Evaluation of Potentially Common Adverse Events Associated With the First and Second Doses of Measles-Mumps-Rubella Vaccine Pediatrics, October 1, 2006; 118(4): 1422 - 1430. [Abstract] [Full Text] [PDF]

				L. S. Nield and D. Kamat Lymphadenopathy in Children: When and How to Evaluate Clinical Pediatrics, January 1, 2004; 43(1): 25 - 33. [PDF]

				M. Virtanen, H. Peltola, M. Paunio, and O. P. Heinonen Day-to-Day Reactogenicity and the Healthy Vaccinee Effect of Measles-Mumps-Rubella Vaccination Pediatrics, November 1, 2000; 106(5): 62e - 62. [Abstract] [Full Text]

				S. L. Katz Harmony on the Second Dose of Measles Vaccine Pediatrics, November 1, 1997; 100(5): 891 - 891. [Full Text] [PDF]